Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pediatric venetoclax monotherapy study in relapsed or refractory malignancies
NL-OMON50736Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of venetoclax in non-Hodgkin lymphoma (NHL), neuroblastoma, acute lymphoblastic leukemia (ALL) and 1 more, sponsored by AbbVie Inc. Started Feb 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)neuroblastomaacute lymphoblastic leukemia (ALL)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON50736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50736.